News - Financing risk management - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

Company news

Efung Honor | Efung Capital Honored with Dual Awards in [FirstNewVoice] 2026 Q2 China's Most Active

Recently, the [FirstNewVoice] 2026 Q2 China's Most Active Institutions Series List was grandly released. Efung Capital was honored with the Top 30 Most Active Venture Capital Institutions in China for Q2 2026 and the Top 10 Most Active Investment Institutions in Healthcare.In the second quarter of 2026, China's equity investment market accelerated its differentiation amid structural recovery, with investment logic, valuation systems, and exit pathways undergoing deeper-level restructuring. According to FirstNewVoice's continuous tracking research over 22 consecutive quarters, nearly 6,000 investment deals were completed in the first half of 2026, with a total value exceeding RMB 560 billion, achieving positive growth for multiple consecutive quarters. Nearly 4,000 new funds were raised, with a scale surpassing RMB 1 trillion. IPO exits exceeded 1,700, and M&A exits approached 370, representing year-on-year increases of nearly 200% and 100%, respectively. ...

2026 - 08 - 07
Efung News | Northchip Life's LotosPFA® Approved for Market Launch! The World's First RCT-Validated

On August 5, 2026, the National Medical Products Administration (NMPA) issued an announcement officially approving the market launch applications for the "Cardiac Pulsed Field Ablation Generator" and the "Single-Use Cardiac Pulsed Field Ablation Catheter," independently developed by Northchip Medical, a subsidiary of Shenzhen Northchip Life Technology Co., Ltd. ("Northchip Life"), under the trade name LotosPFA®. This marks the official entry of PFA into a new era of "routine local anesthesia."The system is the world's first pulsed field ablation (PFA) system validated through a randomized controlled trial (RCT) that supports ablation performed entirely under local anesthesia throughout the entire procedure. It is also the only Chinese PFA product included in the joint scientific statement issued by the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) this February.According to disclosures by Northchip Life and ...

2026 - 08 - 06
Party Building Guides the Investment Path, Bayi Spirit Reflects Our Original Aspiration | EFUNG Capi

August 1, 2026The 99th Anniversary of the Founding of the Chinese People's Liberation ArmyOn this day, when military flags fly high and glory shines bright, EFUNG Capital extends its highest respect to all servicemen and women who have once donned military uniforms and defended our homeland, as well as to their families."A strong country must have a strong military, and only a strong military can ensure national security." Having weathered nearly a century of trials, the People's Army has advanced under the banner of the Party, forging an unbreakable iron bastion. For an investment institution with the mission of "striving for the life sciences," this ironclad faith, discipline, and sense of responsibility are not only the bedrock of national defense, but also the spiritual fuel that empowers us to overcome challenges and navigate market cycles in the capital markets.Party Building Guidance: Party Branch Established on the Company LevelIn 2023, the Party Bra...

2026 - 08 - 01
EFUNG’s Glory | EFUNG Capital Claims Dual Top Honors at Rongzhong 2025-2026 Annual Industry Investme

Recently, Rongzhong officially released its 2025-2026 Annual Industry Investment Rankings. EFUNG Capital was honored as one of the "Best Investment Institutions in China's Healthcare Sector 2025-2026," and CEO Zhu Pai was named one of the "Best Investment Figures in China's Healthcare Sector 2025-2026."The 2026 Government Work Report, for the first time, places the biopharmaceutical industry on par with integrated circuits, aerospace, and low-altitude economy, explicitly designating it as an "emerging pillar industry." This is not merely an iterative update in policy wording, but a fundamental shift in the nation's approach to industrial upgrading and economic transition. For the capital market, investment is no longer about chasing the next hot trend—it is about moving in deep resonance and alignment with the real economy within a structured institutional framework.The ranking was compiled by Rongzhong Research, leveraging its proprietary data...

2026 - 08 - 01
Monthly Health Digest | July 2026

Recently, the General Office of the State Council officially issued the Guiding Opinions on Strengthening Supervision, Preventing Risks, and Promoting the High-Quality Development of Private Investment Funds (State Council Letter No. 54 2026).As a key policy document within the "1+N+X" regulatory framework for the private fund industry, Document No. 54 marks a major shift in private fund supervision — from "industry self-regulation" to "administrative supervision." It represents another significant restructuring of the industry's top-level regulatory system following the Regulations on the Supervision and Administration of Private Investment Funds enacted in 2023.The implementation of this top-level design establishes a clear regulatory tone of "supporting the best, limiting the rest, improving quality, and enhancing efficiency," with particular emphasis on "multi-dimensional cultivation and development of patien...

2026 - 07 - 30
Efung News | Six Portfolio Companies of Efung Capital Make the List! Adding National "Potential Unic

On July 9, at the 2026 Potential Unicorn Enterprise (Wuxi) Development Conference held in Wuxi, Jiangsu, Great Wall Strategy Consulting unveiled the GEI China Potential Unicorn Enterprise Research Report 2026, the seventh edition of this series. Six Efung Capital portfolio companies—TriArm Therapeutics, Shensi Biopharma, Meichuang Medical, Xunlu Biotech, Yinming Biotech, and Jiyin Biotech—were honored on the list.As a new economy consulting firm that pioneered the systematic research and release of unicorn enterprise reports in China, Great Wall Strategy Consulting has continuously researched and published China Unicorn Enterprise Research Reports since 2016, and China Potential Unicorn Enterprise Research Reports since 2020.According to the report, there were 796 potential unicorn enterprises in China in 2025, characterized by a younger structure, frontier-technology dominance, future-industry leadership, and concentrated talent and capital. Over the past seven years, a cumulativ...

2026 - 07 - 29

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务